Coordinatore | INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
Nazionalità Coordinatore | France [FR] |
Totale costo | 185˙748 € |
EC contributo | 185˙748 € |
Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
Code Call | FP7-PEOPLE-2010-IEF |
Funding Scheme | MC-IEF |
Anno di inizio | 2011 |
Periodo (anno-mese-giorno) | 2011-11-02 - 2013-11-01 |
# | ||||
---|---|---|---|---|
1 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | coordinator | 185˙748.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Type II secretion in Gram-negative bacteria is the general exit route for proteins that function outside the cell. During secretion, preproteins are first translocated across the inner membrane, after which the dedicated type II secretion system transports the protein across the outer membrane. In Klebsiella oxytoca the outer membrane pore is formed upon dodecamerisation of PulD, a founder member of the secretin superfamily. The minimal assembly unit of PulD, comprising the transmembrane C-domain preceded by part of the periplasmic N-domain and a short PulS-interaction domain at its C-terminus, assembles spontaneously with high efficiency in vitro in liposomes. The current proposal is aimed at elucidating the folding and assembly mechanism of the minimal PulD dodecamer in vitro. Using a combined approach of mutagenesis and variation of the lipid membrane environment it aims to isolate folding intermediate states along the pathway to the native state. Each intermediate will be characterised structurally by applying a wide range of biophysical and biochemical techniques. Together, these efforts will contribute to our understanding of how sequence determines structure in membrane proteins in the context of a lipid bilayer and at expanding the emerging field of membrane protein folding into more complex systems.'
Protein structure can make a big difference to its function. EU research is applying structural biology to proteins in a multi-drug resistant bacterium that causes sepsis and colitis.
Threatening the health status of patients with an already weakened immune system, Klebsiella oxytoca is a frequent visitor in intensive and elderly care units. Multi-drug resistant strains of Klebsiella are highly virulent and spread rapidly.
Membrane proteins are the key to Klebsiella's success in the infection stakes. One in particular, PulD is crucial to the survival and infectivity of the bacterium. An outer membrane protein, it is part of the machinery for the pore structures. These are vital for the secretion of enzymes, virulence factors (including toxins) and for the assembly of surface pili or hair-like structures.
The FAPUL project has demonstrated the importance of protein folding in the pathway to functionality. A protein will undergo many structural changes during its assembly and folding can be an integral part of its function. The resulting shape is key in terms of interaction with other molecules.
FAPUL researchers showed that PulD protein is part of a multi-step process kicked off by the association of monomers (single unit molecules) with the membrane. An intermediate molecule tightly associated with the membrane was identified as a pre-pore structure that will undergo changes to become the native mature pore.
When the scientists analysed the protein structure, results indicated that there is a switch in conformation or structure to attain the native pore status. To help with the analysis, they developed a mutant library to identify folding intermediates. The exact mechanism is likely to involve interdomain communication to initiate the necessary conformational change.
FAPUL research has provided a firm knowledge base for future research on membrane proteins. Results represent the first step in identification of specific sites for targeted drug action. In the present climate of microbial multi-drug resistance, development of new antimicrobials is crucial to disarm pathogenic bacteria.